Akebia Therapeutics, Inc.
General ticker "AKBA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $591.8M (TTM average)
Akebia Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -29.1%.
Estimated limits based on current volatility of 2.1%: low 1.36$, high 1.41$
Factors to consider:
- Total employees count: 194 (+7.2%) as of 2025
- Top business risk factors: Significant losses, Commercialization failure, Regulatory and compliance, Manufacturing supply issues, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.04$, 2.37$]
- 2026-12-31 to 2027-12-31 estimated range: [1.13$, 2.47$]
Financial Metrics affecting the AKBA estimates:
- Positive: with PPE of -96.0 at the end of fiscal year the price was low
- Positive: Operating cash flow per share per price, % of 16.09 > 12.93
- Positive: Inventory ratio change, % of -3.01 <= -0.75
- Positive: 7.57 < Operating profit margin, % of 9.95
- Positive: -3.72 < Return on assets ratio (scaled to [-100,100]) of -1.40
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: -4.39 < Investing cash flow per share per price, % of -1.88
- Positive: Shareholder equity ratio, % of 8.66 <= 19.19
Short-term AKBA quotes
Long-term AKBA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $194.62MM | $160.18MM | $236.20MM |
| Operating Expenses | $240.88MM | $210.65MM | $212.70MM |
| Operating Income | $-46.26MM | $-50.47MM | $23.50MM |
| Non-Operating Income | $-5.67MM | $-18.94MM | $-27.22MM |
| Interest Expense | $6.03MM | $18.18MM | $24.18MM |
| R&D Expense | $63.08MM | $37.65MM | $62.36MM |
| Income(Loss) | $-51.92MM | $-69.41MM | $-3.72MM |
| Taxes | $0.00MM | $0.00MM | $1.62MM |
| Net Income(Loss)* | $-51.92MM | $-69.41MM | $-5.34MM |
| Stockholders Equity | $-30.58MM | $-49.19MM | $32.61MM |
| Inventory | $15.69MM | $16.24MM | $15.61MM |
| Assets | $241.70MM | $220.67MM | $376.56MM |
| Operating Cash Flow | $-23.38MM | $-40.66MM | $67.99MM |
| Capital expenditure | $0.00MM | $0.03MM | $0.29MM |
| Investing Cash Flow | $0.00MM | $-0.03MM | $-7.93MM |
| Financing Cash Flow | $-25.21MM | $49.66MM | $72.93MM |
| Earnings Per Share** | $-0.28 | $-0.33 | $-0.02 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.